Serologic Cross-Reactivity between the Mumps Virus Vaccine Genotype A Strain and the Circulating Genotype G Strain
Viruses · 2024
DOI: 10.3390/v16091434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Sabaparvin Shaikh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada. Hauptthemen laut MEDLINE: Mumps virus, Cross Reactions, Genotype, Mumps. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Health Agency of Canada intramural, Genomic Research and Development Initiative (GRDI).
Abstract (Originalsprache)
Recent mumps outbreaks have been observed in vaccinated young adults due to the mumps virus (MuV) of genotype G, whereas the current vaccine is a mixture of two genotype A strains. These outbreaks could be attributed to waning vaccine immunity or the antigenic differences between the HN and F glycoproteins in the vaccine and circulating MuV. These glycoproteins are essential targets for the immune system, and antigenic variations may reduce the recognition of mumps antibodies, rendering the population susceptible to the MuV. We established stable cell lines expressing the MuV glycoproteins to study cross-reactivity between genotype A and genotype G. Cross-reactivity between the genotypes was evaluated via immunofluorescence using patient sera from vaccinated individuals, infected individuals, and vaccinated individuals infected with genotype G. Titer ratios showed that the vaccinated individuals exhibited a titer 3.68 times higher for the HN protein and 2.3 times higher for the F protein when comparing genotype A with genotype G. In contrast, the infected individuals showed a lower titer for genotype A compared with genotype G, at 0.43 and 0.33 for the HN and F proteins, respectively. No difference in titer ratio was observed for individuals vaccinated and subsequently infected with mumps. These findings suggest that antigenic variations between the two genotypes may potentially result in immune escape of the circulating strain, resulting in individuals susceptible to the MuV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
- National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
- Cadham Provincial Laboratory, Winnipeg, MB R3E 3J7, Canada.
ORCID-Profile: Jasmine Rae Frost, Elizabeth McLachlan
Förderung
- Public Health Agency of Canada intramural
- Genomic Research and Development Initiative (GRDI)
Zitieren
APA
Shaikh, S., Carpenter, M., Lin, L., Frost, J. R., McLachlan, E., Stein, D., Van Caeseele, P., & Severini, A. (2024). Serologic Cross-Reactivity between the Mumps Virus Vaccine Genotype A Strain and the Circulating Genotype G Strain. Viruses. https://doi.org/10.3390/v16091434
Vancouver
Shaikh S, Carpenter M, Lin L, Frost JR, McLachlan E, Stein D, et al. Serologic Cross-Reactivity between the Mumps Virus Vaccine Genotype A Strain and the Circulating Genotype G Strain. Viruses. 2024. doi:10.3390/v16091434
BibTeX
@article{Shaikh2024,
author = {Shaikh, Sabaparvin and Carpenter, Michael and Lin, Lisa and Frost, Jasmine Rae and McLachlan, Elizabeth and Stein, Derek and Van Caeseele, Paul and Severini, Alberto},
title = {Serologic Cross-Reactivity between the Mumps Virus Vaccine Genotype A Strain and the Circulating Genotype G Strain},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16091434}
}
EUVIMED